Abdul Moiz Siddiqi: Systematic Review Finds Comparable Outcomes for Ticagrelor and Prasugrel in ACS
Abdul Moiz Siddiqi, Bachelor of Medicine and Surgery at Dow Medical College, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Cardiology in Review, adding:
“Alhumdulillah, I am incredibly thrilled to announce my first ever publication!
Our paper ‘Comparative Efficacy and Safety of Ticagrelor and Prasugrel in Acute Coronary Syndrome’ is now published in the ‘Cardiology in Review‘ journal.
Key Takeaways:
- Prasugrel and ticagrelor demonstrated comparable clinical efficacy and safety profiles in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI)
- All-cause mortality occurred in exactly 3.53 percent of patients in both treatment arms, showing zero statistical difference between the two drugs (P=0.66)
- No significant differences were observed across major secondary ischemic outcomes, including cardiovascular death, myocardial infarction, stent thrombosis or stroke
- There is no clear universal winner or drug hierarchy so clinicians should select the P2Y12 inhibitor based on specific patient traits, compliance factors (like once-daily versus twice-daily dosing), tolerability, and explicit contraindications
This is my first ever grand achievement in the field of medicine and research.
I am grateful to have worked alongside incredibly supportive, passionate and professional peers without whom this would not have been possible.
I am specially grateful to Muhammad Ahmed and Shaheer Bin Shafiq my mentors for believing in me and providing me the opportunity to work on this project.”
Title: Comparative Efficacy and Safety of Ticagrelor and Prasugrel in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Clinical Trials
Authors: Shafiq Shaheer Bin, Razzak, Muhammad Junaid Ahmed Muhammad, Khan Ghulam Taha, Siddiqi Abdul Moiz, Bilal Abdur Rafay, Tariq Mansoor Khubaib, Sohaib Asharib, Khan Muhammad Abdullah, Majid Mominah, Ahmed Taha, Abbasi Maham, Waqas Saad Ahmed

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 21, 2026, 03:15Amirabbas Sheykhalo: Silent Mesenteric Ischemia in Portomesenteric Thrombosis
-
Nov 21, 2026, 02:51Ivone Su: Raising Awareness of Venous Thromboembolism
-
Nov 21, 2026, 02:40Aniqa Gohar: One Heart Conclave – Advancing Integrated Thrombosis Care
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop